Note: Ingredients listed on restricted chemical lists
EC/CAS
201-177-9/79-10-7
Name of the chemical
acrylic acid
Concentration
3-<5%
General Information
Version
1,0
Revision date
2023-08-07
Product name
GASKETING COMPOUNDS AN 3510, 3515, 3518, 3573, 3574
Emergency telephone
+49-361-730730
Icons in SDS
Company Information
company name
Nohtec GmbH
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H315, H317, H318, H335, H412
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Hazardous Ingredients
Polyglycol dimethacrylate acrylic acid; prop-2-enoic acid 2'-Phenylacetohydrazide
Signal word
Danger
Hazard statements
Causes skin irritation. May cause an allergic skin reaction. Causes serious eye damage. May cause respiratory irritation. Harmful to aquatic life with long lasting effects.
Precautionary statements
If medical advice is needed, have product container or label at hand. Keep out of reach of children. Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor. Dispose of contents/container to local/regional/national/international regulations.
2.3 Other hazards
The substances in the mixture (> 0.1%) do not meet the PBT/vPvB criteria according to REACH, annex XIII. This product does not contain a substance (> 0,1%) that has endocrine disrupting properties with respect to humans as no components meets the criteria. This product does not contain a substance (> 0,1 %) that has endocrine disrupting properties with respect to non-target organisms as no components meets the criteria.
2.1 Classification of the substance or mixture
Regulation (EC) No 1272/2008 Skin Irrit. 2; H315 Eye Dam. 1; H318 Skin Sens. 1; H317 STOT SE 3; H335 Aquatic Chronic 3; H412 Full text of hazard statements: see SECTION 16.